首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2126393

生物標記檢驗服務市場－策略分析與預測（2026-2035）

Biomarker Validation Services Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計生物標記檢驗服務市場將從 2026 年的 34.2 億美元成長到 2035 年的 87.6 億美元，複合年成長率為 11.0%。

生物標記檢驗服務市場正經歷顯著的變革，其促進因素包括：精準醫療模式轉移、生物標記主導藥物研發日益複雜的過程，以及監管機構對穩健的分析和臨床檢驗的日益重視。這一市場演變的特點在於，人們逐漸認知到，在將生物標記應用於臨床試驗和常規患者管理之前，建立分析準確性、可重複性和臨床有效性至關重要。次世代定序、多組體學平台和液態生物檢體等先進分子技術的融合，增加了檢測的複雜性，並推動了對專業檢驗服務的需求。隨著治療決策越來越依賴分子特徵而非單純的疾病分類，製藥和生物技術公司正在腫瘤學、神經病學、免疫學和心血管疾病等領域擴展基於生物標記的臨床試驗。監管框架正在加強生物標記合格評估，凸顯了標準化檢驗方案在整體臨床開發過程中日益成長的重要性。市場正在對整合生物分析和監管檢驗能力的系統進行大量投資，生物標記檢驗服務被視為推動精準醫療和伴隨診斷發展的關鍵要素。

市場促進因素

精準醫療臨床開發的擴展是生物標記檢驗服務市場的主要驅動力。精準醫療正日益成為現代藥物開發的核心，因為治療效果取決於透過檢驗的生物標記來識別對治療有反應的患者群體。製藥公司正在腫瘤學、免疫學和神經病學領域擴展基於生物標記的臨床試驗，這推動了對分析和臨床檢驗服務的需求。實驗室服務供應商正在加強其分子檢測基礎設施，以滿足日益複雜的檢驗要求。這促使生物標記主導的開發策略得到更廣泛的應用，並持續成長生物標記檢驗服務的使用量。伴隨診斷開發的擴展透過同步治療和診斷方法的檢驗，進一步加速了市場成長。伴隨診斷用於確定患者合格標靶治療的條件，並且需要嚴格的分析檢驗才能獲得監管部門的批准。製藥公司正在將診斷開發更早整合到其臨床項目中，以減少監管方面的不確定性並改善治療效果。檢驗服務供應商正在擴展其檢查室功能和監管合規能力的整合，因為產生一致的證據對於同步治療和診斷應用至關重要。監管機構對生物標記合格的日益重視，推動了對標準化檢驗方案的需求。監管機構正在建立結構化的合格流程，以促進生物標記檢驗的標準化，同時保持科學嚴謹性。合格項目降低了生物標記核准的不確定性，促使申辦方在研發早期階段就與監管機構進行溝通。這種不斷變化的法規環境增加了對能夠產生適用於全球應用的、可重複的分析和臨床證據的檢驗合作夥伴的需求。多體學和先進分子技術的應用增加了檢測的複雜性，導致更多工作外包給專業的檢驗實驗室。多體學平台在加深生物學見解的同時，也引入了分析變異性，需要廣泛的檢驗。製藥公司正在將基因組、轉錄組、蛋白質組和代謝組生物標記納入臨床研究，這進一步增加了檢測的複雜性。

市場限制因素

分析複雜性的不斷增加推高了新型生物標記平台的檢驗成本，並延長了其開發週期。多體學和先進分子技術的複雜性給高效檢驗帶來了挑戰。實驗室間全球標準化程度不足降低了檢測方法的可比較性，並使多中心臨床檢驗試驗更加複雜。缺乏統一的方案也為不同地區檢驗的一致性帶來了挑戰。監管要求不斷變化，導致文件要求更加嚴格，並延緩了未經充分驗證的生物標記的商業化進程。不斷變化的監管環境為尋求檢驗檢驗生物標記的開發人員帶來了不確定性。數據整合和解讀的挑戰進一步增加了多參數生物標記檢驗的複雜性。

對技術和服務類型的洞察

關鍵的技術趨勢是整合分析、生物分析和臨床功能的檢驗平台的重要性日益凸顯。隨著法規核准越來越依賴證明生物標記能夠可靠地預測具有臨床意義的結果，臨床檢驗服務佔據了相當大的市場需求。製藥公司正在腫瘤學和罕見疾病領域擴大基於生物標記的臨床試驗，這增加了對不同患者群體進行統計學上可靠的檢驗研究的需求。由於工作流程碎片化延長了研發週期，檢驗服務提供者正在提供涵蓋生物統計學、實驗室操作和監管文件的綜合服務。次世代定序(NGS) 正在擴展全面的生物標記鑑定能力。 PCR 在特定生物標記的檢測中繼續發揮至關重要的作用。免疫檢測繼續支持蛋白質生物標記的測量。質譜分析擴大應用於全面的蛋白質組學和代謝體學學分析。細分市場分析表明，腫瘤學是最大的治療應用領域。這是因為在標靶治療中，越來越需要在治療開始前基於生物標記進行患者篩選。製藥公司正將基因測序、循環腫瘤DNA (ctDNA) 分析、蛋白質生物標記和多重分析技術納入其臨床開發項目，這增加了檢測的複雜性。在神經病學領域，檢驗要求不斷提高，因為僅靠傳統的臨床評估不足以衡量疾病進展。臨床檢驗仍然是最具戰略意義的檢驗階段，因為僅憑分析性能無法證明其臨床效用。製藥公司佔據了主要的終端用戶群體，而生物技術公司和合約研究組織 (CRO) 也在擴大生物標記的應用。隨著人工智慧 (AI) 透過整合分子資料集、病理圖像和臨床結果來輔助生物標記的優先排序，AI 整合變得越來越重要。由於申辦方要求採用可擴展的分析方法來處理高維生物數據，因此檢驗實驗室正在採用複雜的計算工作流程。

競爭格局與策略展望

競爭格局包括成熟的臨床研究機構和檢測服務供應商，以及專注於生物標記、監管和分析的公司。 IQVIA 的獨特之處在於，它將全球臨床研究營運與先進的醫療保健分析和真實世界數據 (RWE) 能力相結合，從而在整體藥物開發生命週期中提供端到端的生物標記檢驗。 Labcorp Drug Development 憑藉其完善的中心檢查室網路和廣泛的生物標記檢測能力，為全球臨床開發提供支持，從而保持著強大的競爭優勢。該公司提供分析檢驗、生物分析檢測、分子診斷、免疫檢測、流式細胞技術、組織病理學和伴隨診斷的支援。 ICON 透過整合生物標記科學、檢測服務、醫學影像、生物統計學和監管諮詢的臨床開發平台，充分發揮其獨特優勢，為製藥、生物技術和醫療設備公司提供支援。 PAREXEL 的獨特之處在於，它將強大的監管諮詢能力與全球臨床開發專業知識相結合，從而在整個藥物開發生命週期中提供一體化的生物標記檢驗。 Syneos Health 整合了臨床開發、商業化和諮詢能力，為多個治療領域的生物標記主導藥物開發提供支援。各公司均致力於透過多組學體學、人工智慧驅動的分析和整合的監管合規方面的創新來拓展其服務組合。在整合生物標記開發需求的推動下，服務供應商與製藥公司之間的策略合作關係日益增加。近期的重要進展包括：CellCarta推出了一個聯盟，旨在加速藥物開發過程中平台無關的生物標記創新，該聯盟匯集了整體人工智慧病理學合作夥伴，為生物製藥贊助商提供支援。 Aptamer Group 也推出了基於其 Optimer 平台和蛋白質組學分析的生物標記發現服務，加速疾病標記的識別和檢驗。地理擴張仍然是關鍵的策略重點，各公司均瞄準了快速成長的亞太地區和新興市場，這些地區的藥物開發活動正在加速發展。

簡明結論

生物標記檢驗服務市場預計將持續成長，這主要得益於精準醫療、監管重點和技術創新三者的整合。從輔助診斷功能向治療開發核心要素的轉變，標誌著藥物研發領域的根本性變革。儘管分析複雜性、標準化和監管變化等挑戰仍然存在，但對技術、專業知識和綜合能力的策略性投資正為市場領導帶來持續的競爭優勢。生物標記檢驗服務正發展成為精準醫療的關鍵驅動力，支持生物標記的發現、治療開發，並改善全球醫療保健系統中的患者預後，從而帶來光明的長期市場前景。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

按服務類型
- 分析與檢驗服務
- 臨床檢驗服務
- 生物分析檢驗服務
- 監管合規性檢驗和文件編制服務
- 其他
依生物標誌類型
- 基因生物標記
- 蛋白質體學生物標記
- 轉錄組生物標記
- 其他
透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 免疫測量
- 質譜分析
- 其他技術
按治療區域
- 瘤
- 神經病學
- 心血管疾病
- 感染疾病
- 自體免疫/發炎性疾病
- 其他治療領域
檢驗階段
- 分析與檢驗
- 臨床檢驗
- 上市後檢驗
最終用戶
- 製藥公司
- 生技公司
- CRO（委外研發機構）
- 其他

第10章：全球生物標記檢驗服務市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：全球生物標記檢驗服務市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
韓國
印度
澳洲
巴西

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

IQVIA Inc.
Labcorp Drug Development
ICON plc
PAREXEL International Corporation
Charles River Laboratories International, Inc.
Syneos Health, Inc.
Sartorius AG
Thermo Fisher Scientific
SGS SA
Agilent Technologies, Inc.

第14章：全球生物標記檢驗服務市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009105

The Biomarker Validation Services Market is expected to grow at a CAGR of 11.0% from a market value of USD 3.42 billion in 2026 to USD 8.76 billion in 2035.

The biomarker validation services market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the growing complexity of biomarker-driven drug development, and the increasing regulatory emphasis on robust analytical and clinical validation. The market's evolution is characterized by the recognition that establishing analytical accuracy, reproducibility, and clinical relevance is essential before biomarkers can be applied in clinical trials or routine patient management. The convergence of advanced molecular technologies, including next-generation sequencing, multi-omics platforms, and liquid biopsy, is increasing assay complexity and driving demand for specialized validation services. Pharmaceutical and biotechnology companies are expanding biomarker-guided clinical trials across oncology, neurology, immunology, and cardiovascular diseases because treatment decisions increasingly depend on molecular signatures rather than disease classification alone. Regulatory agencies are strengthening biomarker qualification frameworks, increasing the importance of standardized validation protocols throughout clinical development. The market is witnessing significant investment in integrated bioanalytical and regulatory validation capabilities, positioning biomarker validation services as a critical enabler of precision medicine and companion diagnostic development.

Market Drivers

The expansion of precision medicine clinical development represents the primary driver for the biomarker validation services market. Precision medicine increasingly defines modern pharmaceutical development because therapeutic efficacy depends on identifying responsive patient populations through validated biomarkers. Pharmaceutical sponsors are expanding biomarker-guided clinical trials across oncology, immunology, and neurology, creating greater demand for analytical and clinical validation services. Laboratory service providers are strengthening molecular testing infrastructure to accommodate increasingly complex validation requirements, which supports broader adoption of biomarker-driven development strategies, resulting in sustained growth in biomarker validation service utilization. The growth of companion diagnostic development is further accelerating market expansion through synchronized therapeutic and diagnostic validation. Companion diagnostics establish patient eligibility for targeted therapies and therefore require rigorous analytical validation before regulatory approval. Drug developers are integrating diagnostic development earlier within clinical programs to reduce regulatory uncertainty and improve treatment outcomes. Validation service providers are expanding integrated laboratory and regulatory capabilities because synchronized therapeutic and diagnostic submissions require harmonized evidence generation. The increasing regulatory focus on biomarker qualification is strengthening demand for standardized validation protocols. Regulatory agencies establish structured qualification pathways that encourage standardized biomarker validation while maintaining scientific rigor. Sponsors are engaging regulators earlier during development because qualification programs reduce uncertainty regarding biomarker acceptance. This regulatory evolution strengthens demand for validation partners capable of generating reproducible analytical and clinical evidence suitable for global submissions. The adoption of multi-omics and advanced molecular technologies is increasing assay complexity and driving outsourcing to specialized validation organizations. Multi-omics platforms increase biological insight but simultaneously introduce analytical variability that requires extensive validation. Pharmaceutical companies are incorporating genomic, transcriptomic, proteomic, and metabolomic biomarkers into clinical research, increasing assay complexity.

Market Restraints

High analytical complexity increases validation costs and extends development timelines for novel biomarker platforms. The complexity of multi-omics and advanced molecular technologies creates challenges for efficient validation. Limited global standardization across laboratories reduces assay comparability and complicates multicenter clinical validation studies. The lack of harmonized protocols creates challenges for consistent validation across different regions. Regulatory expectations continue evolving, increasing documentation requirements and delaying commercialization for inadequately validated biomarkers. The evolving regulatory landscape creates uncertainty for developers seeking to validate novel biomarkers. Data integration and interpretation challenges create additional complexity for multi-parameter biomarker validation.

Technology and Service Type Insights

The technology landscape is characterized by the growing importance of integrated validation platforms combining analytical, bioanalytical, and clinical capabilities. Clinical validation services account for a significant share of market demand because regulatory approval increasingly depends on demonstrating that biomarkers reliably predict clinically meaningful outcomes. Pharmaceutical companies are expanding biomarker-guided clinical trials across oncology and rare diseases, increasing the need for statistically robust validation studies involving diverse patient populations. Validation providers are integrating biostatistics, laboratory operations, and regulatory documentation within unified service offerings because fragmented workflows extend development timelines. NGS is expanding comprehensive biomarker identification capabilities. PCR remains important for focused biomarker detection. Immunoassays continue supporting protein biomarker measurement. Mass spectrometry is gaining adoption for comprehensive proteomic and metabolomic profiling. The segment analysis reveals that oncology represents the largest therapeutic application because targeted therapies increasingly require biomarker-guided patient selection before treatment initiation. Drug developers are incorporating genomic sequencing, circulating tumor DNA analysis, protein biomarkers, and multiplex molecular diagnostics into clinical development programs, increasing assay complexity. Neurology is generating increasing validation requirements because disease progression remains difficult to measure through conventional clinical assessments alone. Clinical validation remains the most strategically important validation stage because analytical performance alone does not demonstrate clinical utility. Pharmaceutical companies represent the leading end-user segment, with biotechnology companies and CROs expanding biomarker utilization. The integration of AI is becoming increasingly important because AI increasingly supports biomarker prioritization by integrating molecular datasets, pathology images, and clinical outcomes. Validation laboratories are incorporating advanced computational workflows because sponsors require scalable analytical approaches capable of managing high-dimensional biological data.

Competitive and Strategic Outlook

The competitive landscape features established clinical research organizations and laboratory service providers alongside specialized biomarker, regulatory, and analytical companies. IQVIA differentiates itself through its ability to combine global clinical research operations with advanced healthcare analytics and real-world evidence capabilities, enabling end-to-end biomarker validation throughout drug development. Labcorp Drug Development maintains a strong competitive position through its comprehensive central laboratory network and extensive biomarker testing capabilities supporting global clinical development, providing analytical validation, bioanalytical testing, molecular diagnostics, immunoassays, flow cytometry, histopathology, and companion diagnostic support. ICON distinguishes itself through its integrated clinical development platform that combines biomarker science, laboratory services, medical imaging, biostatistics, and regulatory consulting, supporting pharmaceutical, biotechnology, and medical device organizations. PAREXEL differentiates itself through its strong regulatory consulting capabilities combined with global clinical development expertise, enabling integrated biomarker validation throughout the drug development lifecycle. Syneos Health combines clinical development, commercialization, and consulting capabilities to support biomarker-driven drug development across multiple therapeutic areas. Companies are pursuing service portfolio expansion through innovation in multi-omics platforms, AI-enabled analytics, and integrated regulatory support. Strategic collaborations between service providers and pharmaceutical companies are increasing, driven by the need for integrated biomarker development. Recent key developments include CellCarta launching a consortium to accelerate platform-agnostic biomarker innovation across drug development, bringing together several AI pathology partners to support biopharma sponsors. Aptamer Group launched a biomarker discovery service built around its Optimer platform and proteomic analysis to identify and validate disease markers faster. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where pharmaceutical development activity is accelerating.

Short Conclusion

The biomarker validation services market is positioned for sustained growth driven by the convergence of precision medicine, regulatory emphasis, and technological innovation. The transition from a supporting laboratory function into a core element of therapeutic development represents a fundamental shift in pharmaceutical R&D. While challenges related to analytical complexity, standardization, and regulatory evolution persist, strategic investments in technology, expertise, and integrated capabilities are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with biomarker validation services evolving into a critical enabler of precision medicine, supporting biomarker discovery, therapeutic development, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Biomarker Validation Services Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Biomarker Validation Services Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Biomarker Development and Validation Workflow
3.6 Biomarker Categories and Applications
3.7 Drug Development and Companion Diagnostics Landscape
3.8 Historical Market Size Analysis (2021-2025)
3.9 Market Forecast (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Validation Technologies
6.2 Multi-Omics and Precision Medicine Integration
6.3 AI and Machine Learning in Biomarker Validation
6.4 Clinical Trial Biomarker Integration
6.5 Companion Diagnostic Development Trends
6.6 Digital Pathology and Image Biomarker Validation

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Biomarker Validation Services Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Validation Stage
8.3 Analysis by Technology Platform
8.4 Analysis by Therapeutic Area
8.5 Analysis by Biomarker Application

9. Global Biomarker Validation Services Market Segment Analysis (2021-2035)

9.1 By Service Type
- 9.1.1 Analytical Validation Services
- 9.1.2 Clinical Validation Services
- 9.1.3 Bioanalytical Validation Services
- 9.1.4 Regulatory Validation & Documentation Services
- 9.1.5 Others
9.2 By Biomarker Type
- 9.2.1 Genomic Biomarkers
- 9.2.2 Proteomic Biomarkers
- 9.2.3 Transcriptomic Biomarkers
- 9.2.4 Others
9.3 By Technology
- 9.3.1 Next-Generation Sequencing (NGS)
- 9.3.2 Polymerase Chain Reaction (PCR)
- 9.3.3 Immunoassays
- 9.3.4 Mass Spectrometry
- 9.3.5 Other Technologies
9.4 By Therapeutic Area
- 9.4.1 Oncology
- 9.4.2 Neurology
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Infectious Diseases
- 9.4.5 Autoimmune & Inflammatory Diseases
- 9.4.6 Other Therapeutic Areas
9.5. By Validation Stage
- 9.5.1 Analytical Validation
- 9.5.2 Clinical Validation
- 9.5.3 Post Market Validation
9.6 By End User
- 9.6.1 Pharmaceutical Companies
- 9.6.2 Biotechnology Companies
- 9.6.3 Contract Research Organizations (CROs)
- 9.6.4 Others

10. Global Biomarker Validation Services Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Biomarker Validation Services Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 South Korea
11.11 India
11.12 Australia
11.13 Brazil

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 IQVIA Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Service Portfolio
- 13.1.4 Recent Developments
13.2 Labcorp Drug Development
13.3 ICON plc
13.4 PAREXEL International Corporation
13.5 Charles River Laboratories International, Inc.
13.6 Syneos Health, Inc.
13.7 Sartorius AG
13.8 Thermo Fisher Scientific
13.9 SGS SA
13.10 Agilent Technologies, Inc.